Kiniksa Pharmaceuticals International plc reported robust financial results for the second quarter of 2025, with total revenue reaching $156.8 million, a significant increase from $108.6 million in the same period of 2024. The growth was primarily driven by ARCALYST, with net product revenue for the quarter also totaling $156.8 million, marking a 52% year-over-year growth. The company reported a net income of $17.8 million for Q2 2025, a notable improvement from the net loss of $3.9 million reported in the second quarter of the previous year. Total operating expenses increased to $136.6 million from $108.7 million in the same period last year, with collaboration expenses contributing significantly due to ARCALYST collaboration profitability. As of June 30, 2025, Kiniksa's cash, cash equivalents, and short-term investments stood at $307.8 million, with no debt reported. The company has updated its financial guidance, expecting ARCALYST net product revenue for the full year 2025 to be between $625 million and $640 million, an increase from the prior guidance of $590 million to $605 million. Additionally, Kiniksa expects to maintain cash flow positivity on an annual basis under its current operating plan. In terms of business operations, Kiniksa initiated a Phase 2/3 clinical trial for KPL-387 in recurrent pericarditis, with Phase 2 data anticipated in the second half of 2026.